EAGAN, Minn.--(BUSINESS WIRE)--Biothera announced today that it has initiated enrollment of patients in a phase Ib/IIa clinical trial to evaluate the safety and efficacy of Imprime PGG™ and Erbitux® in patients with metastatic colorectal cancer. Imprime PGG is a unique biological response modifier that enhances specific innate immune cell responses without inducing pro-inflammatory cytokines. Erbitux (cetuximab) is a monoclonal antibody from ImClone Systems that is approved for treatment of colorectal and head and neck cancer.
